CMHC Share Price Performance
CHF 0
-57.10 (-100.00%)
Price CHF 0
Fair ValueCHF 92.09
Share Pricen/a
Cosmo N.V. Stock Price
- 4 Narratives written by author
- 2 Comments on narratives written by author
- 163 Fair Values set on narratives written by author
CMHC Community Narratives
AN
Fair Value
·Fair Value CHF 92.09 38.0% undervalued intrinsic discount
EMA Hurdles And Generics Will Stall Growth But Enable Recovery
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value CHF 159.65 64.2% undervalued intrinsic discount
Aging Populations And AI Will Advance Precision Medtech
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value CHF 123.72 53.8% undervalued intrinsic discount
Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges
1users have liked this narrative
2users have commented on this narrative
38users have followed this narrative
EMA Hurdles And Generics Will Stall Growth But Enable Recovery
Cosmo Pharmaceuticals is growing on the back of a few standout treatments and new digital health tools, but that same narrow focus could turn into a problem if approvals drag on or competitors catch up. With tougher pricing, more copycat drugs, and slow regulators in the mix, the path to a smooth recovery looks far less certain than it first appears.Read more
AN
CHF 92.09
38.0% undervalued intrinsic discount
Fair Value
Profit Margin
6.91%
Future PE
183.78x
Price in 2029
CHF 101.49
Aging Populations And AI Will Advance Precision Medtech
Cosmo Pharmaceuticals is trying to turn its AI-assisted endoscopy tool into a broader software platform, with big-name partners helping it reach more hospitals and new types of procedures. The upside comes with real catches—much of today’s business still leans on a small set of gut-focused medicines, and approvals, pricing pressure, or partner missteps could slow the story.Read more
AN
CHF 159.65
64.2% undervalued intrinsic discount
Fair Value
Profit Margin
48.42%
Future PE
17.92x
Price in 2029
CHF 172.11
Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges
Key Takeaways Strategic expansion in AI-powered diagnostics and proprietary drug delivery platforms positions Cosmo for sustained revenue growth, margin expansion, and competitive differentiation in global healthcare markets. Advances in specialty pharmaceuticals and digital transformation, supported by global partnerships, provide multiple growth drivers, diversified earnings streams, and enhanced operational efficiency.Read more
AN
CHF 123.72
53.8% undervalued intrinsic discount
Fair Value
Profit Margin
25.98%
Future PE
44.11x
Price in 2029
CHF 133.25
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
COPN: Higher Projected Margins And P/E Will Support Future Upside Potential
Fair Value: CHF 92.09 38.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
COPN: Late-Stage Alopecia Data And Higher Assumptions Will Support Future Earnings Potential
Fair Value: CHF 159.65 64.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
COPN: Higher Revenue Assumptions And Single Investor Placement Will Support Upside
Fair Value: CHF 123.72 53.8% undervalued intrinsic discount
38 fair values setusers have set this as their fair value
2 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cosmo N.V. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.37
- 45.51%
- -6.19%
- 0.05%
About CMHC
- Founded
- 1997
- Employees
- 365
- CEO
- WebsiteView website
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers’ diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo’s AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.
